Back to results
US 5,854,025 AGranted
IGF-II analogues
AssigneeBritish Biotech Pharmaceutical, Ltd.
InventorsRichard Mark Edwards, Lindsay Bawden
Life of this patent
Estimating the term…
Abstract
Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino acid residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
Claims13
An isolated nucleic acid molecule coding for an Insulin-like Growth Factor II (IGF-II) analogue, wherein at least one of R37 and R38 of SEQ. ID NO:
- 1 is replaced with another amino acid residue, wherein R37 represents the natural arginine residue at position 37 and R38 represents the natural arginine residue at position 38.
Dependencies are inferred from the claim text.